Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Cash on Hand

<< Previous

Bullboard Posts

Next >>

Comment by themagicboxon Jan 10, 2021 1:22pm

165 Views

Post# 32263433

RE:RE:RE:RE:RE:Cash on Hand

in his latest biopub he said its worth x2-x4 its current amount.

Best to keep expectation graded. Dan had mentioned 75% likelihood partnership vs 25% buyout.

I'm very bullish on ATE but I've disappointed many times before. Hopefully the corporate update is next week to give indication of the direction we're heading towards.

3burtc wrote: Has Dan made any comments recently to what the company is worth? We know that revenue will average 2.8 billion per year, otezla sold for 8 times revenue.

<< Previous

Bullboard Posts

Next >>

A Look into the Future of Chronic Pain Management